Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study
Abstract The St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer treatment. The main purpose of this article is to ascertain the clinical factors associated with St Gallen-2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed with pa...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6f26e14184d2444e9a5708bb0af06235 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6f26e14184d2444e9a5708bb0af06235 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:6f26e14184d2444e9a5708bb0af062352021-12-02T15:53:03ZAdequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study10.1038/s41598-021-84825-22045-2322https://doaj.org/article/6f26e14184d2444e9a5708bb0af062352021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84825-2https://doaj.org/toc/2045-2322Abstract The St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer treatment. The main purpose of this article is to ascertain the clinical factors associated with St Gallen-2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed with pathological stage < 3 in Spain between 2008 and 2013 was begun and then followed-up until 2017/2018. Data on patient and tumour characteristics were obtained from medical records, as well as their first line treatment. First line treatments were classified in three categories, according on whether they included the main St Gallen-2013 recommendations, more than those recommended or less than those recommended. Multinomial logistic regression models were carried out to identify factors associated with this classification and Weibull regression models were used to find out the relationship between this classification and survival. About half of the patients were treated according to St Gallen recommendations; 21% were treated over what was recommended and 33% received less treatment than recommended. Factors associated with treatment over the recommendations were stage II (relative risk ratio [RRR] = 4.2, 2.9–5.9), cancer positive to either progesterone (RRR = 8.1, 4.4–14.9) or oestrogen receptors (RRR = 5.7, 3.0–11.0). Instead, factors associated with lower probability of treatment over the recommendations were age (RRR = 0.7 each 10 years, 0.6–0.8), poor differentiation (RRR = 0.09, 0.04–0.19), HER2 positive (RRR = 0.46, 0.26–0.81) and triple negative cancer (RRR = 0.03, 0.01–0.11). Patients treated less than what was recommended in St Gallen had cancers in stage 0 (RRR = 21.6, 7.2–64.5), poorly differentiated (RRR = 1.9, 1.2–2.9), HER2 positive (RRR = 3.4, 2.4–4.9) and luminal B-like subtype (RRR = 3.6, 2.6–5.1). Women over 65 years old had a higher probability of being treated less than what was recommended if they had luminal B-like, HER2 or triple negative cancer. Treatment over St Gallen was associated with younger women and less severe cancers, while treatment under St Gallen was associated with older women, more severe cancers and cancers expressing HER2 receptors.Inés Gómez-AceboTrinidad Dierssen-SotosMónica MironesBeatriz Pérez-GómezMarcela GuevaraPilar AmianoMaria SalaAntonio J. MolinaJéssica Alonso-MoleroVictor MorenoClaudia Suarez-CallejaAna Molina-BarcelóJuan AlguacilRafael Marcos-GrageraMaría Fernández-OrtizOscar Sanz-GuadarramaGemma Castaño-VinyalsLeire Gil-MajueloConchi Moreno-IribasNuria AragonésManolis KogevinasMarina PollánJavier LlorcaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Inés Gómez-Acebo Trinidad Dierssen-Sotos Mónica Mirones Beatriz Pérez-Gómez Marcela Guevara Pilar Amiano Maria Sala Antonio J. Molina Jéssica Alonso-Molero Victor Moreno Claudia Suarez-Calleja Ana Molina-Barceló Juan Alguacil Rafael Marcos-Gragera María Fernández-Ortiz Oscar Sanz-Guadarrama Gemma Castaño-Vinyals Leire Gil-Majuelo Conchi Moreno-Iribas Nuria Aragonés Manolis Kogevinas Marina Pollán Javier Llorca Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study |
| description |
Abstract The St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer treatment. The main purpose of this article is to ascertain the clinical factors associated with St Gallen-2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed with pathological stage < 3 in Spain between 2008 and 2013 was begun and then followed-up until 2017/2018. Data on patient and tumour characteristics were obtained from medical records, as well as their first line treatment. First line treatments were classified in three categories, according on whether they included the main St Gallen-2013 recommendations, more than those recommended or less than those recommended. Multinomial logistic regression models were carried out to identify factors associated with this classification and Weibull regression models were used to find out the relationship between this classification and survival. About half of the patients were treated according to St Gallen recommendations; 21% were treated over what was recommended and 33% received less treatment than recommended. Factors associated with treatment over the recommendations were stage II (relative risk ratio [RRR] = 4.2, 2.9–5.9), cancer positive to either progesterone (RRR = 8.1, 4.4–14.9) or oestrogen receptors (RRR = 5.7, 3.0–11.0). Instead, factors associated with lower probability of treatment over the recommendations were age (RRR = 0.7 each 10 years, 0.6–0.8), poor differentiation (RRR = 0.09, 0.04–0.19), HER2 positive (RRR = 0.46, 0.26–0.81) and triple negative cancer (RRR = 0.03, 0.01–0.11). Patients treated less than what was recommended in St Gallen had cancers in stage 0 (RRR = 21.6, 7.2–64.5), poorly differentiated (RRR = 1.9, 1.2–2.9), HER2 positive (RRR = 3.4, 2.4–4.9) and luminal B-like subtype (RRR = 3.6, 2.6–5.1). Women over 65 years old had a higher probability of being treated less than what was recommended if they had luminal B-like, HER2 or triple negative cancer. Treatment over St Gallen was associated with younger women and less severe cancers, while treatment under St Gallen was associated with older women, more severe cancers and cancers expressing HER2 receptors. |
| format |
article |
| author |
Inés Gómez-Acebo Trinidad Dierssen-Sotos Mónica Mirones Beatriz Pérez-Gómez Marcela Guevara Pilar Amiano Maria Sala Antonio J. Molina Jéssica Alonso-Molero Victor Moreno Claudia Suarez-Calleja Ana Molina-Barceló Juan Alguacil Rafael Marcos-Gragera María Fernández-Ortiz Oscar Sanz-Guadarrama Gemma Castaño-Vinyals Leire Gil-Majuelo Conchi Moreno-Iribas Nuria Aragonés Manolis Kogevinas Marina Pollán Javier Llorca |
| author_facet |
Inés Gómez-Acebo Trinidad Dierssen-Sotos Mónica Mirones Beatriz Pérez-Gómez Marcela Guevara Pilar Amiano Maria Sala Antonio J. Molina Jéssica Alonso-Molero Victor Moreno Claudia Suarez-Calleja Ana Molina-Barceló Juan Alguacil Rafael Marcos-Gragera María Fernández-Ortiz Oscar Sanz-Guadarrama Gemma Castaño-Vinyals Leire Gil-Majuelo Conchi Moreno-Iribas Nuria Aragonés Manolis Kogevinas Marina Pollán Javier Llorca |
| author_sort |
Inés Gómez-Acebo |
| title |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study |
| title_short |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study |
| title_full |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study |
| title_fullStr |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study |
| title_full_unstemmed |
Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study |
| title_sort |
adequacy of early-stage breast cancer systemic adjuvant treatment to saint gallen-2013 statement: the mcc-spain study |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/6f26e14184d2444e9a5708bb0af06235 |
| work_keys_str_mv |
AT inesgomezacebo adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT trinidaddierssensotos adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT monicamirones adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT beatrizperezgomez adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT marcelaguevara adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT pilaramiano adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT mariasala adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT antoniojmolina adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT jessicaalonsomolero adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT victormoreno adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT claudiasuarezcalleja adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT anamolinabarcelo adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT juanalguacil adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT rafaelmarcosgragera adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT mariafernandezortiz adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT oscarsanzguadarrama adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT gemmacastanovinyals adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT leiregilmajuelo adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT conchimorenoiribas adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT nuriaaragones adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT manoliskogevinas adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT marinapollan adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy AT javierllorca adequacyofearlystagebreastcancersystemicadjuvanttreatmenttosaintgallen2013statementthemccspainstudy |
| _version_ |
1718385515420450816 |